ChromaDex Corporation - CDXC STOCK NEWS

ChromaDex Corp. (NASDAQ:CDXC) will host a webinar on July 20, 2022, at 11:00 am ET featuring Dr. Charles Brenner, a leading expert on nicotinamide adenine dinucleotide (NAD). The session will cover the benefits of nicotinamide riboside (NR) and its role in boosting NAD levels, essential for metabolic processes and cellular repair.Tru Niagen®, ChromaDex's flagship supplement, will also be highlighted. A live Q&A session will follow, and registration is open to the public.

ChromaDex (NASDAQ: CDXC) is enhancing awareness of its research at key conferences, including ASN Nutrition 2022, ISSN, and FASEB’s NAD+ Metabolism and Signaling Conference. The company’s CERP™ program has over 250 material transfer agreements with 235 scientists across 182 institutions. During ASN, presentations will cover topics like NAD+ impact on immune function and cognition. ChromaDex’s involvement aims to highlight the importance of nicotinamide riboside, a precursor to NAD+, for healthy aging and athletic performance.

ChromaDex Corp. (NASDAQ: CDXC) has signed a distribution agreement with Sinopharm Xingsha to enhance cross-border sales of Tru Niagen in China. This partnership aims to amplify brand awareness and secure Health Food Registration in the region, as part of their recent Joint Venture. Currently valued at $700 million in annual sales, the NAD+ supplement market in China is projected to exceed $1.5 billion by 2024. Tru Niagen is backed by scientific research and regulatory approvals across various regions, positioning ChromaDex to capitalize on China's aging population.

ChromaDex Corp. (NASDAQ:CDXC) has announced that CEO Rob Fried and CFO Kevin Farr will present at Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference on June 15 at 3:45 p.m. Eastern Time. The presentation will be virtual, and the management team will also engage in one-on-one meetings with institutional investors throughout the day. ChromaDex is committed to healthy aging, focusing on research related to nicotinamide adenine dinucleotide (NAD+) and its precursor, nicotinamide riboside (NR), marketed as Niagen®.

ChromaDex Corp. (NASDAQ:CDXC) has partnered with Juvenis to launch its Tru Niagen^® supplement in South Korea. Tru Niagen^®, a leading Vitamin B3 product, aims to boost NAD⁺ levels and is recognized for its health benefits. With South Korea projected to see a 23% increase in its elderly population by 2050, the partnership seeks to meet growing demands for health supplements. The product will be available on major platforms including NaverSmartStore and Gmarket. ChromaDex continues to lead research in NAD⁺ supplementation.

ChromaDex Corp. (NASDAQ:CDXC) will present virtually at the 12th Annual Invitational on June 8, at 4:30 p.m. ET. The event will feature over 200 companies, and ChromaDex's CEO Rob Fried and CFO Kevin Farr will lead the presentation. Additionally, the management team will hold one-on-one meetings with institutional investors throughout the day. Interested parties can find more information and the webcast link on the LD Micro website. ChromaDex is focused on healthy aging and is known for its NAD+ precursor, Niagen®.

ChromaDex Corp. (NASDAQ:CDXC) has announced the establishment of a joint venture, ChromaDex Asia, aimed at distributing its product, Tru Niagen®, in mainland China. The new venture includes partners Crystal Lake Developments, Pioneer Idea Holdings, and Hong Kong Taikuk. Successful commercialization hinges on approval from China's State Administration for Market Regulation, which is critical for health food registration. CEO Rob Fried emphasized this move as a significant milestone in the company’s strategy for the Chinese market, with the JV's formation contingent upon customary closing conditions.

ChromaDex Corp. (NASDAQ:CDXC) reported first-quarter 2022 net sales of $17.3 million, marking an 18% increase year-over-year, primarily driven by a 20% rise in Tru Niagen® sales to $14.9 million. The gross margin decreased to 61.0% from 62.9% due to changes in business mix and increased supply chain costs. Operating expenses rose to $18.3 million, resulting in a net loss of $7.7 million or $(0.11) per share. For 2022, the company anticipates 15-20% revenue growth, with ongoing investment in brand awareness and R&D, despite potential COVID-19 headwinds.